<DOC>
	<DOC>NCT01103011</DOC>
	<brief_summary>The study hypothesis is that continuous ND0611 increases the bioavailability of levodopa and therefore the levodopa area-under-the-concentration-curve values, half-life, and trough concentrations The study will help determining the safety and tolerability of ND0611 and determine the pharmacokinetic profile of levodopa following multiple oral dosing of levodopa/carbidopa (LD/CD) and continuous delivery of ND0611</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Healthy Caucasian males between 18 and 50 years (inclusive) of age Normal body weight Subjects with negative urinary drugs of abuse, HIV, Hepatitis B or Hepatitis C serology tests Subjects must be able to adhere to the protocol requirements Subjects must provide written informed consent to participate in the study. Haemoglobin level &gt;12.5 mg /dl History of significant psychiatric disorder, neurological diseases or sleep disorders History of significant systemic diseases, by medical history or tests performed during screening examinations Clinically significant laboratory tests at screening History of drug or alcohol abuse. Allergy to levodopa, carbidopa or any inactive component of the test formulation. Subjects with dark skin Subjects with skin diseases or neoplasms Subjects with narrowangle glaucoma Subjects with significant allergic response to other drugs. Subject with known atopic disorders Known allergy or hypersensitivity to adhesive tapes. Use of any prescription or overthecounter (OTC) medications Subjects who donated blood or received blood, in the last 3 months Participation in another clinical trial in the last 30 days Subjects which do not have the ability to communicate well or will not adhere to the protocol procedures</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>